Neuroone Medical Technologies (NMTC) EBIAT (2016 - 2025)
Neuroone Medical Technologies (NMTC) has disclosed EBIAT for 14 consecutive years, with -$1.4 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, EBIAT fell 180.54% year-over-year to -$1.4 million, compared with a TTM value of -$6.8 million through Dec 2025, up 5.0%, and an annual FY2025 reading of -$3.6 million, up 70.73% over the prior year.
- EBIAT was -$1.4 million for Q4 2025 at Neuroone Medical Technologies, up from -$1.6 million in the prior quarter.
- Across five years, EBIAT topped out at $1.8 million in Q4 2024 and bottomed at -$3.5 million in Q1 2023.
- Average EBIAT over 5 years is -$2.4 million, with a median of -$2.8 million recorded in 2022.
- The sharpest move saw EBIAT soared 153.37% in 2024, then plummeted 180.54% in 2025.
- Year by year, EBIAT stood at -$2.8 million in 2021, then skyrocketed by 38.28% to -$1.7 million in 2022, then tumbled by 93.04% to -$3.3 million in 2023, then skyrocketed by 153.37% to $1.8 million in 2024, then tumbled by 180.54% to -$1.4 million in 2025.
- Business Quant data shows EBIAT for NMTC at -$1.4 million in Q4 2025, -$1.6 million in Q3 2025, and -$1.5 million in Q2 2025.